Veterinary Pain Management Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)

Veterinary Pain Management Market Dynamics

Rise of Monoclonal Antibody Therapies for Targeted Pain Relief Is the Key Trend

• Monoclonal antibody therapies have become a significant trend in veterinary pain management because they provide precise medical interventions with extended duration while ensuring patient safety.
• These biologics function differently from standard painkillers through their ability to treat pain sources at the molecular level.
• The growing market demand for veterinary science-based treatment drives this trend forward.
• The medical field prefers monoclonal antibodies because they provide extended pain relief benefits to chronic conditions without the adverse effects that conventional medications cause.

Increasing Prevalence of Disorders in Animals Are the Major Growth Driver

• According to the National Cancer Institute, an estimated 65 million dogs and over 32 million cats in the U.S. are suffering from cancer, with roughly 6 million cancer diagnoses occurring each year.
• This huge population of animals with cancer provides an opportunity for the growth of the market, as pain is the most common clinical symptom of the illness. Hence, there is a considerable need for safe and effective pain management in animals worldwide.
• Moreover, due to the increasing prevalence of various disorders, there has been a significant rise in the number of veterinarians practicing in the U.S., which stood at 121,461 in 2021, compared to 118,624 in 2020.
• This trend also reflects the broader humanization of pets, where animals are increasingly treated as family members, leading to higher expectations for veterinary care and greater demand for advanced, humane pain management options.

Veterinary Pain Management Market Segmentation Analysis

Product Analysis

The drug category held the larger market share, of 85%, in 2024. The most prevalent drugs in this segment are NSAIDs which primarily treat chronic conditions such as osteoarthritis. These medications are popular because they effectively manage pain and have simple administration methods and economical costs. Pet owners frequently choose oral NSAIDs since these drugs offer both practicality and powerful pain management for long-term conditions. The widespread regulatory approvals with clinical guidelines have made NSAIDs the standard first-line pain treatment choice for veterinarians throughout the world.

The device category will grow at a higher CAGR, of 8.5%, during the forecast period. This is because veterinary patients require treatments that avoid pharmaceutical medications and invasive procedures beyond conventional pain management approaches. The targeted pulsed electromagnetic field (tPEMF) therapy system offers tissue repair and pain relief benefits without the usual side effects of drug-based treatments. The combination of rising pet owners seeking holistic drug-free treatments and improved veterinary technology has driven the increasing market adoption. Devices used for medical therapy continue to expand their market presence because of their growing application in post-operative care and chronic disease monitoring.

The products analyzed here are:

• Drug (Larger Category)
  • By Type
    • NSAIDs
    • Opioids
    • Local Anesthetics
    • Alpha-2 Agonists
    • Disease-Modifying Osteoarthritis Agents
  • By Route of Administration
    • Oral
    • Parenteral
    • Topical
• Device (Faster-Growing Category)
  • Laser Therapy Device
  • Electromagnetic Device

Application Analysis

The joint pain category held the largest market share, of 55%, in 2024. The prevalence of osteoarthritis in senior dogs and cats leads to this high need for treatment. Osteoarthritis impacts between 20% of adult canine patients and elder pet animals at rates above the adult dog percentage according to the American College of Veterinary Surgeons. The long-lasting character of this medical condition leads to extensive pain treatment needs which establishes this application as a money-making sector.

The cancer pain category will grow at a highest CAGR, of 8.1%, during the forecast period.
Advances in companion animal cancer diagnosis rate estimated at 6 million new canine cases per year within the U.S. have increased demand for improved pain management solutions. The progression of veterinary oncology alongside prolonged pet treatment requires pain management to become an essential element of complete care.

The applications analyzed here are:

• Joint Pain (Largest Category)
  • Osteoarthritis
  • Musculoskeletal
• Cancer Pain (Fastest-Growing Category)
• Postoperative Pain

Animal Type Analysis

The companion animal category held the larger market share, of 60%, in 2024. The high occurrence of chronic health conditions including osteoarthritis cancer and post-surgical pain affects dogs and cats specifically because they need ongoing pain relief treatments. Pet insurance growth across North America and parts of Europe together with improved veterinary services keeps this market segment active. For instance, in September 2022, Zoetis Inc. announced its acquisition of Jurox, an animal health company that develops, manufactures, and markets a wide range of veterinary medicines for livestock and companion animals. Through this acquisition, Zoetis has earned access to a broad range of products, including Alfaxan, an anesthetic product for companion animals.

The livestock animal category will grow at a higher CAGR, of 8.4%, during the forecast period, because owners now recognize both animal welfare as well as productivity benefits of appropriate pain treatments. The management of pain for livestock animals produces positive effects on healing rates and mobility as well as milk and meat production which drives researchers to focus on this area. The advancement of animal welfare regulations is driving veterinary experts and livestock producers to extend the practice of pain relief throughout their operations.

Moreover, in March 2020, Ceva Animal Health launched a cattle campaign, ‘Wave Goodbye to Pain’, to spotlight how proper pain relief in lame cattle can speed up recovery time and improve results. These types of campaigns raise awareness among veterinary professionals and farmers, in turn, accelerating the market growth.

Additionally, companion animals receive more specialized care and medical attention from their owners than production animals, which is a major factor boosting the market revenue in this category.

The animal types analyzed here are:

• Companion Animal (Larger Category)
  • Dog
  • Cat
  • Horse
• Livestock Animal (Faster-Growing Category)
  • Cattle
  • Swine

End User Analysis

The veterinary hospitals category held the larger market share, of 75%, in 2024 and will grow at a higher CAGR, of 9%, during the forecast period. This is because they possess advanced diagnostic equipment along with surgical practices and broad pain management solutions that include medication-based and device-based therapies. Hospitals treat more complicated cases of orthopedic surgeries and cancer treatments along with other chronic secondary conditions that need complex pain relief techniques. Patients rely on hospitals as their main source for complete pain management services as hospitals offer inpatient care management surgical treatment and long-term therapeutic solutions. Modern technology investments at clinics allow them to deliver outpatient pain management services, particularly for osteoarthritis patients and those recovering from surgery.

The expanding pet population in urban and suburban regions causes clinics to function as primary healthcare providers for prevention and chronic pain assessment thus driving their growth in developed and emerging markets. Furthermore, the growing incidence of bacterial conditions in companion animals, especially dogs, is contributing to the increase in the number of veterinary hospitals. For instance, in the U.S., there are approximately 30,000 veterinary practices, among which 10% are general companion animal practices and 40–50% are referral practices.

The end users analyzed here are:

• Veterinary Hospitals (Larger and Faster-Growing Category)
• Veterinary Clinics

Veterinary Pain Management Market Regional Outlook

The North America held the largest market share, of 40%, in 2024. This is because this region maintains a strong veterinary healthcare infrastructure combined with heightened awareness for animal welfare. The U.S. commands market leadership because its population of companion animals exceeds 66 percent of U.S. households as reported by the American Pet Products Association. Additionally, the widespread availability of pet insurance, increasing veterinary visits, and high spending on animal healthcare of over $35 billion in veterinary care expenditures in 2023 alone, contribute to the region’s dominance.

The North American market maintains its market leadership position because of the dominant presence of Zoetis alongside Elanco and Merck & Co. Furthermore, the growing investments in research and development in the well-established animal health industry are propelling the growth of the market. For instance, in June 2022, Boehringer Ingelheim partnered with CarthroniX to explore the utility of small molecules for cancer treatment in dogs. This collaboration will emphasize identifying new molecules to target cancers in dogs, as small molecules could give superior disease control.

The APAC region will grow at a higher CAGR, of 9.5% during the forecast period because consumers have increased purchasing power and urban areas are expanding simultaneously with rising animal healthcare knowledge. The pet adoption trend is rapidly increasing in China and India where pet ownership is expanding by 12% annually throughout India along with quick economic growth for pets in Chinese urban areas. The combination of government investments to enhance veterinary facilities with expanding multinational animal health businesses drives rapid market expansion within this area. Market expansion in the Asia-Pacific region will create significant business opportunities during the next few years.

The regions analyzed in this report are:

• North America (Largest Category)
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific (Fastest-Growing Category)
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of LATAM
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • U.A.E.
  • Rest of MEA

Veterinary Pain Management Market Competitive Landscape

The veterinary pain management market demonstrates high fragmentation because multiple players from global and regional sectors supply diverse products and solutions across the market. The competitive environment expands through innovations that include improved drug delivery approaches non-medicinal treatment options and customized healthcare solutions. Zoetis Inc. controls the biggest market portion due to its extensive product diversity, and its worldwide presence, along with sustained research funding. This market shows ongoing expansion because people understand animal welfare better pet ownership is increasing and veterinarians need specific pain medications for both pets and farm animals.

Veterinary Pain Management Market News

• In February 2025, Zoetis obtained U.S. regulatory approval to expand the labeling of Librela for treating osteoarthritis pain in dogs. The product label received an update that shows rare side effects such as seizures and paralysis but Zoetis maintains that the product remains safe and effective.
• In April 2024, Dechra partnered with Fear Free to improve the veterinary experience by developing techniques that help reduce pet anxiety at clinics. Dechra demonstrates their dedication to enhancing animal welfare by using Fear Free's behavioral techniques through their partnership.